公开(公告)号：US10426783B2

公开(公告)日：2019-10-01

申请号：US15387113

申请日：2016-12-21

Applicant: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION ,  KOWA COMPANY, LTD.

Inventor： Tatsuro Ishibashi ,  Shintaro Nakao ,  Ryoichi Arita ,  Ken Mizuno ,  Akifumi Tsuchiura

IPC: A61K31/551 ,  A61K9/00 ,  A61K31/496 ,  C07D401/12 ,  A61K47/10

Abstract: Disclosed herein is a prophylactic or therapeutic agent for ocular fundus disease, especially diabetic retinopathy or age-related macular degeneration. The prophylactic or therapeutic agent for ocular fundus disease comprising: (S)-(−)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine, a salt thereof, or a solvate thereof, as an active ingredient.

公开(公告)号：US20190274824A1

公开(公告)日：2019-09-12

申请号：US16424051

申请日：2019-05-28

Applicant: KOWA COMPANY, LTD.

Inventor： Asaki SUZAKI

IPC: A61F2/16 ,  G02C7/02

Abstract: Provided is an intraocular lens having a novel structure with high utility which is easy to adapt to patients, and can improve quality of vision (QOV). In an intraocular lens, an optical characteristic is set rotationally symmetric around an optical axis, and a spherical aberration of a size corresponding to a coma aberration remaining in a patient's eye after extraction of a human lens of the eye is set.

公开(公告)号：US20190224169A1

公开(公告)日：2019-07-25

申请号：US16227440

申请日：2018-12-20

Applicant: Kowa Company, Ltd.

Inventor： Ryu Oshima ,  Kazuhito Suehira ,  Gary Gordon

IPC: A61K31/4168 ,  A61P3/06

Abstract: The present invention relates to pharmacological interventions with pemafibrate for moderate or severe hypertriglyceridemia.

公开(公告)号：US10314825B2

公开(公告)日：2019-06-11

申请号：US15903279

申请日：2018-02-23

Applicant: KOWA COMPANY, LTD.

Inventor： Mitsumasa Nakamura ,  Satoshi Kojima ,  Ryohei Tanigawa

IPC: A61K31/423 ,  A61P1/16 ,  A61K31/575

Abstract: The present invention relates to a pharmaceutical composition for the treatment of primary biliary cirrhosis (PBC), in which containing a therapeutically effective amount of (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy] butyric acid, a salt thereof, or a solvate thereof.

公开(公告)号：US10310358B2

公开(公告)日：2019-06-04

申请号：US15504419

申请日：2015-09-07

Applicant: KOWA COMPANY, LTD.

Inventor： Shuichi Tominaga ,  Suguru Hanzawa

IPC: G02B7/02 ,  G03B9/06 ,  G02B5/00

Abstract: In the present invention, an edge face of an diaphragm ring (4) has a part (a locked portion) wherein a plurality of depressions (62) are formed and a substantially flat surface portion wherein no depression (62) is formed, and by a simple operation of operating a link releaser (52) so as to rotate the diaphragm ring (4), it is possible to switch between a click mode and a non-click mode. When taking still images, a diaphragm value can be fixed by using the click mode, and when video is taken, the diaphragm value can be smoothly changed during imaging by using the non-click mode.

公开(公告)号：US10295839B2

公开(公告)日：2019-05-21

申请号：US15317192

申请日：2015-04-27

Applicant: KOWA COMPANY, LTD

Inventor： Hirofumi Yagi

IPC: G02B7/02 ,  G02B27/64 ,  G03B9/02 ,  G03B15/00 ,  G03B17/14 ,  H04N5/225 ,  H04N5/232

Abstract: [Problem] To make it possible to prevent vibrations or the like from causing focus or zoom slippage or the like in a lens that is mounted to a camera body that is used in a fixed location outdoors for many years for security purposes or is used inside a building that is subject to a variety of variations, such as a camera that is used for quality-checking purposes or the like at a production site in a factory.[Solution] The lens barrel (1) in this invention has the following: a fixed tube section (10) that is mounted to a camera body (B); a movable tube section (20) that is movably screwed to the fixed tube section (10); and a nut member (12) that, screwed to the movable tube section (20), is energized towards top end (10b) of the fixed tube section (10). The nut member (12) acts as a double nut, making it possible to inhibit rotation of the fixed tube section (10) and the movable tube section (20) relative to each other, preventing focus or zoom slippage or the like.

公开(公告)号：US10285587B2

公开(公告)日：2019-05-14

申请号：US15551973

申请日：2016-02-25

Applicant: KOWA COMPANY, LTD.

Inventor： Yusuke Izawa

IPC: A61B3/14 ,  A61B3/12 ,  A61B3/15 ,  A61B3/00

Abstract: [Problem] To allow imaging light to be appropriately received by a second camera in the case where a first imaging mode (color imaging mode) is changed to a second imaging mode (autofluorescence imaging mode). [Solution] In the first imaging mode, using a dichroic mirror 30 allows light LB to be received by both a first camera C1 and a second camera C2. In the second imaging mode, using a transparent glass 31 allows light LB to be received by the second camera C2. With this configuration, both in the first imaging mode and in the second imaging mode, light LB from an ocular fundus is appropriately received by the second camera C2 whereby an appropriate ocular fundus image can be taken.

公开(公告)号：US20190124293A1

公开(公告)日：2019-04-25

申请号：US16092015

申请日：2017-04-21

Applicant: KOWA COMPANY, LTD.

Inventor： Tomohisa AZEGAMI ,  Tatsuya KIMBARA

IPC: H04N7/08 ,  H04N5/247 ,  H04N17/00 ,  H04N7/10

Abstract: [Problem] To make a device compact and inexpensive by omitting a frame buffer.[Solution] First packet data PD1 that is sequentially received from a first camera C1 and second packet data PD2 that is sequentially received from a second camera C2 are alternately and sequentially transmitted to an external device 2 before data for one screen is accumulated. Therefore, a frame buffer for saving the data for one screen is not necessary, and a device can be made correspondingly more compact and less expensive.

公开(公告)号：US10258609B2

公开(公告)日：2019-04-16

申请号：US15904922

申请日：2018-02-26

Applicant: KOWA COMPANY, LTD.

Inventor： Toshiaki Takizawa ,  Yasunobu Yoshinaka

IPC: A61K31/423 ,  A61K31/397 ,  A61K45/06

Abstract: The present invention addresses the problem of providing a pharmaceutical combination composition and drug combinations for the prevention and/or treatment of dyslipidemic conditions such as atherosclerosis, hypercholesterolemia, low HDL blood disease in mammals including humans. A pharmaceutical composition for the prevention and/or treatment of dyslipidemia, etc. which comprises (a) a compound represented by the general formula (1) (in the formula, each symbol is the same as defined in the specification) or a salt thereof or a solvate thereof and (b) a cholesterol absorption inhibitor.

公开(公告)号：US20190091008A1

公开(公告)日：2019-03-28

申请号：US16092188

申请日：2017-04-07

Applicant: Kowa Company, Ltd.

Inventor： Haruo ISHIKAWA

IPC: A61F2/16

Abstract: A toric intraocular lens includes a lens body, support portions, and connecting portions for connecting the lens body and the support portions. The lens is housed in an insertion apparatus that includes a tubular apparatus body having an insertion tube for the lens and a plunger for moving the lens. Each of the connecting portions is arranged at a position where the connecting portions face each other across a center of an optical axis of the lens body. One end of the flat meridian of the lens body is located at a position opposite to a position, with respect to an axis that passes through the center and connects the connecting portions, at which the plunger contacts the lens body. An angle between the flat meridian and an axis along which the lens is pushed by the plunger is larger than 0° and equal to or smaller than 90°.